AstraZeneca Nolvadex
Executive Summary
Breast cancer risk reduction consumer brochure was not submitted to FDA at time of initial dissemination, agency tells company in July 20 letter. AstraZeneca has received at least three previous ad division letters regarding promotion of tamoxifen for breast cancer risk reduction